This fund primarily allocates its capital to common equities. A substantial portion, specifically at least 80% of its total assets, is dedicated to companies deeply involved in the biotechnology industry. This encompasses businesses engaged in the research, development, manufacturing, and distribution of biotechnological products, services, and processes, as well as those poised to benefit significantly from scientific and technological advancements in the field.
